Non-Small Cell Lung Cancer Market Size and Share : Global Industry Expansion Strategies, Future Growth, Emerging Demands, Opportunity Assessment and Demand Forecast by 2033


 A recently published study by FMI expects the global Non-Small Cell Lung Cancer Market to augment at a 7.2% CAGR from 2023 to 2033. By the end of the said assessment period, a valuation of US$ 20 Billion is expected for the market. From 2018 to 2022, the industry experienced noteworthy growth, registering a value CAGR of 6.7% and closing at US$ 10 Billion. The expansion of the non-small cell lung cancer market may be attributed to an increase in cancer cases as well as increased patient knowledge about their health.

Non-small cell lung cancer, one of the most common kinds of lung cancer, reduces the lungs' ability to provide oxygen to the blood. Non-small cell lung cancer accounts for 80-85% of all lung cancer cases worldwide. The causes are passive smoking, active smoking, consuming polluted water, and being exposed to air pollution. It can, however, be treated with a variety of medicines such as immunotherapy, targeted therapy, and others.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16143

The two primary causes of non-small cell lung cancer are excessive tobacco intake and active participation in passive smoking. Long-term air pollution exposure promotes the development of non-small cell lung cancer. However, the existence of large firms, as well as the entry of new essential players, will result in excessive market rivalry. This will decrease the rate of expansion of the lung cancer treatments market.

The high expense of therapy or treatment will limit the scope of expansion even further. Because of the prevalence of advanced healthcare infrastructure, greater research and development capabilities by pharmaceutical firms, and quick adoption of new and better healthcare technology, North America leads the non-small cell lung cancer market. Asia-Pacific, on the other hand, is expected to have the greatest growth rate throughout the projection period due to increased healthcare infrastructure spending, increasing prevalence of non-small cell lung cancer, and a growing senior population sensitive to cancer.

Key Takeaways from the Market Study

  • FMI projects the global non-small cell lung cancer market to expand at a 7.2% value CAGR by 2033
  • The global non-small cell lung cancer market is estimated at a market value of US$ 10 Billion
  • The global non-small cell lung cancer market is expected to garner a market value of US$ 20 Billion
  • North America is forecast to be the most lucrative for non-small cell lung cancer market growth.
  • As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 6.7% during the assessment period 2023-2033.
  • Europe is expected to grow at a CAGR of 7% during the assessment period 2023-2033.
  • The chemotherapy segment is expected to hold the largest market share for non-small cell lung cancer in the forecast period 2023-2033.

“Rising investment in research & development efforts by the key players will fuel market expansion even more,” says an analyst at FMI

Market Competition

Key players in the non-small cell lung cancer market are Novartis Pharmaceuticals, Merck KGaA, Eli Lilly and Company, Hoffmann-La Roche, Xcovery, BeyondSpring Pharmaceuticals, OSE Immunotherapeutics, Sanofi, Takeda, and AbbVie.

Recent Developments:

  • In December 2022, Pluvicto®, a targeted radioligand treatment, has been authorised by the European Commission (EC), according to Novartis. Pluvicto® is licensed for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer in conjunction with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition (mCRPC). AR pathway inhibitor and taxane-based chemotherapy were used to treat these individuals.

More Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the global non-small cell lung cancer mrket, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023-2033.

The study reveals essential insights on the basis of Cancer Type Squamous Cell Carcinoma, Adenocarcinoma and Large-cell Carcinoma, by Treatment (Chemotherapy, Targeted Therapy and Immunotherapy), across five major regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).

Key Segments Profiled in the Non-Small Cell Lung Cancer Industry Survey

Non-Small Cell Lung Cancer Market by Cancer Type:

  • Squamous Cell Carcinoma
  • Adenocarcinoma
  • Large-cell Carcinoma

Non-Small Cell Lung Cancer Market by Treatment:

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy

Comments

Post a Comment

Popular posts from this blog

Non-Vascular Stents Market to 2032 – Global Analysis and Forecasts by Types, Technologies, Applications and End-User Verticals

Image
 The Non-Vascular Stents Market is expected to grow at a CAGR of  4.5%  over the forecast period. (2022 - 2032). The sector is expected to be valued at  US$ 1.21 billion  in 2022 and  US$ 1.9 billion by 2032. The global non-vascular stents market is expected to move forward in response to the growing demand for minimally-invasive procedures. Rising technological and material advancements are assisting in the development of specially designed stents for use in a variety of indications thereby fueling the overall non-vascular stents market growth. Non-vascular stents use small, precise incisions, resulting in scars that are smaller and less visible than those left by traditional surgical techniques, putting the patient's safety in jeopardy. The above-mentioned feature is anticipated to provide impetus to the non-vascular stents market adoption trends in coming years. Such a surgery is associated with a faster recovery period, resulting in a shorter hospital stay for the patient, enc
Read more

Teleradiology Services Market Analysis And Demand With Forecast Overview To 2032

Image
 In 2022, it is expected that the Teleradiology Services Market would be worth around US$ 31,880.57 Million. By 2032, it is anticipated that the market for teleradiology services would reach US$5,598.3 Million. with a 19% CAGR growth forecast through 2032. The global Teleradiology Services Market is estimated to reach a market valuation of US$ 1,971.4 Million by the end of 2016 and register a CAGR of 21.0% over the forecast period (2016–2026). The growth of this market can be attributed to the favorable government initiatives regarding the adoption of teleradiology in order to provide early disease diagnosis. Besides, the application of modern-day technologies such as the adoption of cloud-based technologies, blockchain, and cryptocurrencies will lead to better efficiency and cost-effective solutions. Increasing Investments for the development of advanced solutions is augmenting the demand for the industry. Request Sample PDF Brochure: https://www.futuremarketinsights.com/reports/samp
Read more

From X-rays to AI: Veterinary Imaging Innovations of the Next Decade By 2022 to 2030

Image
  Between 2022 and 2030, the global veterinary imaging industry is expected to grow at a CAGR of 6.6%, from US$ 2.02 billion in 2022 to US$ 3.37 billion by 2030. A study by Future Industry Insights (FMI) predicted that by 2030, the worldwide veterinary imaging industry would bring in US$ 3.37 billion. The research study looks at the market development for veterinary imaging through 2030 in more than 20 nations. The report offers precise insights into some of the key players in the industry's crucial business strategies. According to the poll, investments are being made in the veterinary diagnostics industry as the trend towards pet humanization picks up speed. Additionally likely to fuel industry growth are governmental rules and a greater emphasis on preserving animal health. Request A Report Sample To Gain Comprehensive Insights! https://www.futuremarketinsights.com/reports/sample/rep-gb-12368 Growth will also be fueled by the expansion of the animal and pet care industry as a w
Read more